105 related articles for article (PubMed ID: 15325383)
1. Comparison of two methods for the analysis of [18F]6-fluoro-L-m-tyrosine PET data.
Eberling JL; Pivirotto P; Bringas J; Bankiewicz KS
Neuroimage; 2004 Sep; 23(1):358-63. PubMed ID: 15325383
[TBL] [Abstract][Full Text] [Related]
2. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with 4-[18F]fluoro-L-m-tyrosine in MPTP-induced hemiparkinsonian monkeys.
Hayase N; Tomiyoshi K; Watanabe K; Horikoshi S; Shibasaki T; Ohye C
Ann Nucl Med; 1995 Aug; 9(3):119-23. PubMed ID: 8534583
[TBL] [Abstract][Full Text] [Related]
7. 6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates.
Jordan S; Eberling JL; Bankiewicz KS; Rosenberg D; Coxson PG; VanBrocklin HF; O'Neil JP; Emborg ME; Jagust WJ
Brain Res; 1997 Mar; 750(1-2):264-76. PubMed ID: 9098552
[TBL] [Abstract][Full Text] [Related]
8. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
[TBL] [Abstract][Full Text] [Related]
9. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
Eberling JL; Jagust WJ; Taylor S; Bringas J; Pivirotto P; VanBrocklin HF; Bankiewicz KS
Brain Res; 1998 Sep; 805(1-2):259-62. PubMed ID: 9733979
[TBL] [Abstract][Full Text] [Related]
10. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.
Cropley VL; Fujita M; Bara-Jimenez W; Brown AK; Zhang XY; Sangare J; Herscovitch P; Pike VW; Hallett M; Nathan PJ; Innis RB
Psychiatry Res; 2008 Jul; 163(2):171-82. PubMed ID: 18504119
[TBL] [Abstract][Full Text] [Related]
11. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
[TBL] [Abstract][Full Text] [Related]
12. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain.
Nahmias C; Wahl L; Chirakal R; Firnau G; Garnett ES
Mov Disord; 1995 May; 10(3):298-304. PubMed ID: 7651447
[TBL] [Abstract][Full Text] [Related]
13. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
14. Relationship of striatal dopamine synthesis capacity to age and cognition.
Braskie MN; Wilcox CE; Landau SM; O'Neil JP; Baker SL; Madison CM; Kluth JT; Jagust WJ
J Neurosci; 2008 Dec; 28(52):14320-8. PubMed ID: 19109513
[TBL] [Abstract][Full Text] [Related]
15. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Eberling JL; Pivirotto P; Bringas J; Bankiewicz KS
Exp Neurol; 2000 Oct; 165(2):342-6. PubMed ID: 10993693
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.
Melega WP; Raleigh MJ; Stout DB; DeSalles AA; Cherry SR; Blurton-Jones M; Morton GG; Huang SC; Phelps ME
Exp Neurol; 1996 Oct; 141(2):318-29. PubMed ID: 8812167
[TBL] [Abstract][Full Text] [Related]
17. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine.
Tabbal SD; Mink JW; Antenor JA; Carl JL; Moerlein SM; Perlmutter JS
Neuroscience; 2006 Sep; 141(3):1281-7. PubMed ID: 16766129
[TBL] [Abstract][Full Text] [Related]
18. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA.
DeJesus OT; Endres CJ; Shelton SE; Nickles RJ; Holden JE
J Nucl Med; 1997 Apr; 38(4):630-6. PubMed ID: 9098215
[TBL] [Abstract][Full Text] [Related]
20. Visualization of dopamine nerve terminals in monkey by positron emission tomography using 4-[18F]fluoro-L-m-tyrosine.
Hayase N; Tomiyoshi K; Watanabe K; Horikoshi S; Hirato M; Shibasaki T; Ohye C
Stereotact Funct Neurosurg; 1994; 62(1-4):191-6. PubMed ID: 7631066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
